:quality(85)/cloudfront-us-east-1.images.arcpublishing.com/infobae/KHJABTJ465FSBK6P6FXZDHPCTI.jpg)
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/GP2ZXWJRROQQUNBAGJPH3WIOVQ.jpg)
:quality(85)/cloudfront-us-east-1.images.arcpublishing.com/infobae/SHKALTVTXZHNDGR226XZGZFS6E.jpg)
An accompanying meta-analysis supports the analgesic benefit of CGRP receptor antagonists, among many other options, as acute treatment.
One third of patients have an inadequate response to current acute treatments.
According to the study, the potential for acute treatment to provide a preventive benefit and Therapy Preventive action with acute effects is an “interesting advance”.
Eptinezumab, a calcitonin gene-related peptide (CGRP) antibody, speeds up the resolution of symptoms when taken within the first six hours of the onset of a migraine.
An accompanying meta-analysis supports the analgesic benefit of CGRP receptor antagonists, among many other options, as acute treatment.
The combined primary efficacy end points were time to headache absence and time to absence of the most bothersome symptoms (nausea, photophobia, or phonophobia).
The main secondary end points were no headache Absence of the most bothersome symptoms two hours after the start of the infusion. Additional secondary end points were no headache No more bothersome symptoms after 4 hours and rescue medication within 24 hours.
Among patients eligible for migraine prophylaxis who experienced a moderate to severe migraine attack, treatment with intravenous eptinezumab versus placebo reduced the time to headache and symptom resolution.
The feasibility of administering eptinezumab during a migraine attack and comparing it with alternative therapies has not yet been demonstrated.
The source referenced here: US National Library of Medicine
